Brief: Poxel's PXL065, PXL770 Granted Orphan Drug Designation By FDA

Poxel SA

17/05/2022 17:23

May 17 (Reuters) - Poxel SA  POXEL.PA :
    * ANNOUNCES PXL065 AND PXL770 GRANTED ORPHAN DRUG
DESIGNATION FROM
THE U.S. FDA FOR X-LINKED ADRENOLEUKODYSTROPHY
    * BOTH COMPOUNDS ARE PREPARING TO ENTER INTO PHASE 2A
CLINICAL
PROOF-OF-CONCEPT (POC) BIOMARKER STUDIES AS SOON AS POSSIBLE,
SUBJECT TO FINANCING

Source text for Eikon:  ID:nBw5fKBBha 
Further company coverage:  POXEL.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48587696600;))